- Halozyme CEO Helen Torley reported exercise of options for 10,000 common shares at USD 12.07 on April 6, 2026.
- She also sold 10,000 common shares on April 6 at weighted average prices of USD 63.14 and USD 64.02.
- Torley beneficially owned 767,780 Halozyme common shares following transactions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000048), on April 07, 2026, and is solely responsible for the information contained therein.
Comments